Literature DB >> 9158060

Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis.

G W Anderson1, P L Worsham, C R Bolt, G P Andrews, S L Welkos, A M Friedlander, J P Burans.   

Abstract

Monoclonal antibodies (MAbs) to the fraction 1 (F1) protein of Yersinia pestis protected mice against fatal pneumonic as well as bubonic plague from wild-type F1+ organisms. The rare isolation of a virulent F1- isolate from surviving animals supports earlier studies suggesting that improved vaccines should consist of immunogens to protect against F1- variants. The high degree of protection with IgG MAb suggests that secretory IgA is not required for protection from pneumonic plague.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9158060     DOI: 10.4269/ajtmh.1997.56.471

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  46 in total

1.  Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis.

Authors:  Jim Hill; Catherine Copse; Sophie Leary; Anthony J Stagg; E Diane Williamson; Richard W Titball
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

2.  Deletion of Braun lipoprotein and plasminogen-activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague.

Authors:  Christina J van Lier; Jian Sha; Michelle L Kirtley; Anthony Cao; Bethany L Tiner; Tatiana E Erova; Yingzi Cong; Elena V Kozlova; Vsevolod L Popov; Wallace B Baze; Ashok K Chopra
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Administration of antibody to the lung protects mice against pneumonic plague.

Authors:  Jim Hill; Jim E Eyles; Stephen J Elvin; Gareth D Healey; Roman A Lukaszewski; Richard W Titball
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.

Authors:  Debaditya Bhattacharya; Joan Mecsas; Linden T Hu
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

5.  Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles.

Authors:  Jayaprakash Babu Uppada; Arif Azam Khan; Ajaz Ahmad Bhat; Ranjana Deshmukh; Donthamsetty Nageswara Rao
Journal:  Med Microbiol Immunol       Date:  2009-09-25       Impact factor: 3.402

6.  Antibody Opsonization Enhances Early Interactions between Yersinia pestis and Neutrophils in the Skin and Draining Lymph Node in a Mouse Model of Bubonic Plague.

Authors:  Jeffrey G Shannon; B Joseph Hinnebusch
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

7.  Yersinia pestis IS1541 transposition provides for escape from plague immunity.

Authors:  Claire A Cornelius; Lauriane E Quenee; Derek Elli; Nancy A Ciletti; Olaf Schneewind
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

8.  Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model.

Authors:  Xiaodong Xiao; Zhongyu Zhu; Jennifer L Dankmeyer; Michael M Wormald; Randy L Fast; Patricia L Worsham; Christopher K Cote; Kei Amemiya; Dimiter S Dimitrov
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

9.  Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis.

Authors:  Deyan Luo; Jr-Shiuan Lin; Michelle A Parent; Isis Mullarky-Kanevsky; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Michael Tighe; Jim Hill; Andras Gruber; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2013-03-13       Impact factor: 5.422

10.  D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.

Authors:  Frank M Szaba; Lawrence W Kummer; Lindsey B Wilhelm; Jr-Shiuan Lin; Michelle A Parent; Sara W Montminy-Paquette; Egil Lien; Lawrence L Johnson; Stephen T Smiley
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.